Idioma:

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

ACT Investigators

Circulation (New York, N.Y.), 2011-09, Vol.124 (11), p.1250-1259 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por

Enviar para

Título:
Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)
Autor: ACT Investigators
Assuntos: Acetylcysteine - therapeutic use ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - prevention & control ; Aged ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular system ; Contrast Media - adverse effects ; Coronary Angiography - adverse effects ; Coronary Angiography - methods ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; Humans ; Kidney Diseases - chemically induced ; Kidney Diseases - prevention & control ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic - methods ; Treatment Outcome ; Vasodilator agents. Cerebral vasodilators
É parte de: Circulation (New York, N.Y.), 2011-09, Vol.124 (11), p.1250-1259
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury. We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; P=0.97). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; P=0.92). Consistent effects were observed in all subgroups analyzed, including those with renal impairment. In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography. http://www.clinicaltrials.gov. Unique identifier: NCT00736866.
Editor: Hagerstown, MD: Lippincott Williams & Wilkins
Idioma: Inglês

Links

Voltar para lista de resultados

Resultado 1

Realização: Logos de Redes Sociais:

Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT)

ACT Investigators

Hagerstown, MD: Lippincott Williams & Wilkins

Buscando em bases de dados remotas. Favor aguardar.